These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 14763026)

  • 1. Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency.
    Ishida Y; Tomori K; Nakamoto H; Imai H; Suzuki H
    Adv Perit Dial; 2003; 19():10-4. PubMed ID: 14763026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
    Nakamoto H; Imai H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S83-7. PubMed ID: 18552271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
    Ponchon P; Elghozi JL
    Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive action of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride in hypertensive rat models.
    Tanaka M; Yamamoto S; Nakao K; Inukai T; Ogawa N; Katsumura H; Ohara N; Shukunobe K; Ono H
    Arzneimittelforschung; 1991 Jun; 41(6):608-12. PubMed ID: 1930348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats.
    Wang YX; Gavras I; Wierzba T; Gavras H
    J Lab Clin Med; 1992 Mar; 119(3):267-72. PubMed ID: 1541876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
    Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
    Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity.
    Barra JG; Levenson J; Armentano RL; Cabrera Fischer EI; Pichel RH; Simon A
    Am J Physiol; 1997 Feb; 272(2 Pt 2):H859-68. PubMed ID: 9124449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension.
    Higashi Y; Oshima T; Sasaki S; Nakano Y; Kambe M; Matsuura H; Kajiyama G
    Hypertension; 1998 Jul; 32(1):16-24. PubMed ID: 9674632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of losartan on short-term variability of blood pressure of renovascular hypertensive rats: a spectral study.
    Ponchon P; Grichois ML; Elghozi JL
    J Hypertens Suppl; 1993 Dec; 11(5):S244-5. PubMed ID: 8158366
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
    Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T
    Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
    Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
    Choi SM; Seo MJ; Kang KK; Kim JH; Ahn BO; Yoo M
    Arch Pharm Res; 2009 Mar; 32(3):353-8. PubMed ID: 19387578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.